AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 33 min read$RVTY

Revvity: Q3 Earnings Snapshot

Revvity, Inc. (RVTY) reported Q3 profit of $62.3M, or 56 cents per share, with adjusted EPS of $1.38, beating estimates. Revenue was $728.9M, also surpassing forecasts. The company expects full-year EPS of $5.40-$5.45 and revenue of $2.86B.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 11:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Revvity: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$RVTYBullishMed
01

Why it matters

The key tradable inputs are the Q3 adjusted EPS and revenue beats versus consensus, plus the stated full-year EPS and revenue expectations that update forward estimates.

02

Market read

Company-specific earnings beat and explicit full-year EPS guidance typically drive same-day repricing and near-term options/positioning.

03

What to watch

The article does not break out segment performance, backlog, or margin drivers, so traders may reprice only after deeper earnings-call details emerge.

Relevance 8/10Novelty 8/10Timing: reported Tuesday, before/at market open window (per timestamp)

Background

AP summary of Revvity’s Q3 results and full-year outlook, citing analyst expectations from Zacks.

Company-level read

Ticker impact

$RVTYBullishHigh confidence
Context

Revvity reported Q3 profit of $62.3M and adjusted EPS of $1.38, beating the $1.29 consensus, and issued full-year EPS guidance of $5.40 to $5.45.

Expected impact

Likely upward bias as the market digests the EPS and revenue beat and the specific full-year earnings range.

Evidence & confidence

The article provides fresh, company-specific quarterly results and explicit full-year guidance, which are direct inputs to earnings models and positioning.

Market effects

Sector

Scientific instruments and lab tools peers may see modest read-across on demand and margins, but this is single-company guidance.

Regional

Limited, mostly US small-to-mid cap earnings sentiment rather than a broad regional catalyst.

Global

Low, as the disclosure is company-specific with no stated global macro or regulatory shock.

Counterpoint

What could challenge this read

A guidance range can still disappoint if investors expected a higher midpoint or if the beat was driven by one-offs not reflected in adjusted metrics.

Key entities

  • company
    Revvity, Inc.

    Maker of scientific instruments reporting Q3 results and full-year guidance.

  • source
    Zacks Investment Research

    Provided the analyst consensus estimates referenced in the article.

Read at source← All news

StoryRevvity beats Q3 expectations and raises 2026 guidance

Also covered by

4 outlets

Related articles

NOV 3
$RVTYMed

Revvity, Inc. Q3 2026 Earnings Call Summary

Revvity, Inc. reported Q3 2026 earnings, highlighting a 9% organic growth in Life Sciences, driven by reagent and software demand. Management raised full-year guidance to 5% growth, citing AI-related demand and operational efficiencies. The company expects sustainable margins and plans to divest its China immunodiagnostics business in 2027. Key growth areas include reagents and Signals software, with AI-native offerings launching in 2026.

finance.yahoo.com7 min
NOV 3
$RVTYHighAI 9/10

Revvity Shares Jump Nearly 6% as Q3 Earnings Beat Forecasts and 2026 Guidance Improves

Revvity (RVTY) shares rose 5.55% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 vs. $1.30 expected. Revenue grew 4% YoY to $729M, surpassing forecasts. Pro forma revenue, excluding China Immunodiagnostics, increased 7% to $710M. Life Sciences revenue grew 10.8% to $380M, while Diagnostics saw a 2% reported decline but 4% pro forma growth.

finance.yahoo.com5 min
NOV 3
$RVTYHighAI 8/10

Revvity Q3 2026 slides: strong growth, margin expansion lift outlook

Revvity reported Q3 2026 revenue of $710M, up 7% YoY, with adjusted operating margins expanding to 29.4%. EPS grew 21% to $1.37. The company raised full-year guidance, citing strong demand and operational improvements. Life Sciences and Diagnostics segments showed growth, with the Americas and Europe outperforming Asia-Pacific. Revvity's stock surged 8.85% premarket to $165.01.

investing.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Shares Jump After Strong Q3, Raises Outlook

Revvity shares rose 8.8% premarket after Q3 2026 earnings beat expectations, with adjusted EPS at $1.37 and revenue at $729M. The company raised FY 2026 guidance, targeting $5.40–$5.45 EPS and $2.86B revenue. Life Sciences segment grew 11%, and operating margin improved to 13.1%. CEO attributed results to strong execution. TD Cowen raised its price target to $175 in October.

tradingpedia.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Announces Financial Results for the Third Quarter of 2026

REVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE November 3, 2026 Revvity Announces Financial Results for the Third Quarter of 2026 • Revenue of $729 million; pro forma revenue of $710 million; 7% pro forma revenue growth; 7% pro forma organic revenue growth • GAAP EPS from continuing operations of $0.56 ;

SEC EDGAR 8-K2 min